Clinical Trial: Phase I Study of Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07032714) titled 'Phase I Study of Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma' on June 16.

Brief Summary: This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Cohort A will receive talquetamab + dexamethasone, then mezigdomide + talquetamab,+ dexamethasone. After Cohort A, Cohort B will evaluate mezigdomide + dexamethasone followed by step-up dosing of talquetamab (mezigdomide + talquetamab,+ dexamethasone).

Study Start Date: Dec. 16, 2025

Study Type: INTERVENTIONAL

Condition: ...